Claim Therapeutics

CLAIM Therapeutics is a German biotechnology company focused on the discovery and development of novel cancer immunotherapies and precision medicines. Headquartered in Hamburg, the company operates as the drug discovery arm of the Indivumed Group, leveraging the proprietary IndivuType multi-omics database to identify high-confidence therapeutic targets. By analyzing deep molecular profiles from thousands of patient tissue samples, CLAIM Therapeutics aims to develop first-in-class therapies for solid tumors with high unmet medical needs. Their lead program, CT-101, is a monoclonal antibody targeting G protein-coupled receptor 15 (GPR15), identified through their advanced bioinformatics platform. The company's approach integrates artificial intelligence and multi-omic data to accelerate the transition from target discovery to clinical validation. CLAIM Therapeutics focuses on addressing cancer heterogeneity to provide more effective, personalized treatment options for patients globally.